Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: An overview

Clinical Drug Investigation

Volumn 15, Issue 4, 1998, Pages 337-351

  Baldessarini, Ross J ^a,c   Tondo, Leonardo ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; OXCARBAZEPINE; PSYCHOTROPIC AGENT; VALPROIC ACID;

ARTICLE; BIPOLAR DEPRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; HUMAN; KIDNEY DISEASE; MANIC DEPRESSIVE PSYCHOSIS; META ANALYSIS; METABOLIC DISORDER; METHODOLOGY; MORBIDITY; MORTALITY; OBESITY; PHARMACODYNAMICS; PRIORITY JOURNAL; RECURRENCE RISK; SUICIDAL BEHAVIOR; TERATOGENESIS; THYROID DISEASE;

EID: 0031945851     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199815040-00010     Document Type: Article

References (80)

1. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990: 665-724
2. Kessler RC, McGonigle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity study. Arch Gen Psychiatry 1994; 51: 8-19
3. Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry 1976; 11: 31-42
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. DSM-IV. Washington, DC: American Psychiatric Association, 1994
5. Shulman KI. Mania in the elderly. Int Rev Psychiatry 1993; 5: 445-53
6. Tohen M, Shulman KI, Satlin A. First-episode mania in late life. Am J Psychiatry 1994; 151: 130-32
7. Faedda GL, Baldessarini RJ, Suppes T, et al. Pediatric-onset bipolar disorder: a neglected clinical and public health problem. Harvard Rev Psychiatry 1995; 3: 171-95
8. Baldessarini RJ, Tondo L, Suppes T, et al. Pharmacological treatment of bipolar disorder throughout the life-cycle. In: Shulman KI, Tohen M, Kutcher S, editors. Bipolar disorder through the life-cycle. New York: John Wiley & Sons, 1996: 299-338
9. Tondo L, Baldessarini RJ, Floris G, et al. Lithium maintenance treatment reduces risk of suicidal behavior in bipolar disorder patients. In: Gallicchio VS, Birch NJ, editors. Lithium: biochemical and clinical advances. Cheshire, CT: Weidner Publishing Group, 1996: 161-71
10. Tondo L, Jamison K, Baldessarini RJ. Antisuicide effects of lithium. Ann NY Acad Sci 1997; 863: 339-51
11. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment reduces risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. In press
12. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 213-9
13. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-52
14. Schou M. Lithium. Arch Gen Psychiatry 1997; 54: 9-13
15. Baldessarini R. Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. Chapter 19. In: Hardman JG, Limbird LE, Molinoff PB, et al. editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York, McGraw-Hill Press, 1996: 431-59
16. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carhamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-50
17. Prien RF, Gelenberg AJ. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry 1989; 146: 840-8
18. Post RM, Leverich GS, Rosoff AS, et al. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990; 10: 318-27
19. Pope Jr HG, McElroy SL, Keck Jr PE, et al. Valproate in the treatment of acute mania: placebo-controlled study. Arch Gen Psychiatry 1991; 48: 62-8
20. Patsalos PN, Duncan JS. New antiepileptic drugs: a review of their current status and clinical potential. CNS Drugs 1994; 2: 40-77
21. Balfour JA, Bryson HM. Valproic acid: a review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs 1994; 2: 144-73
22. Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153: 765-70
23. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Pharmacopsychiatry 1996; 29: 103-7
24. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996; 153: 993-1000
25. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146-50
26. Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 1989; 50: 127-31
27. Kocsis JH, Shaw ED, Stokes PE, et al. Neuropsychologic effects of lithium discontinuation. J Clin Psychopharmacology 1993; 13: 268-76
28. Coppen A, Abou-Saleh MT, Wood KM, et al. Decreasing lithium dosage reduces morbidity and side-effects during prophylaxis. J Affect Disord 1983; 5: 353-62
29. Maj M, Starace F, Nolfe G, et al. Minimum plasma lithium levels required for effective prophylaxis in DSM-III bipolar disorder: a prospective study. Pharmacopsychiatry 1986; 19: 420-3
30. Baldessarini RJ, Cohen, BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91
31. Waters B, Lapierre Y, Gagnon A, et al. Determination of the optimal concentration of lithium for the prophylaxis of manic-depressive disorder. Biol Psychiatry 1982; 17: 1323-9
32. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489-93
33. Rosenbaum JF, Sachs GS, Lafer B, et al. High rates of relapse in bipolar patients abruptly changed from standard to low plasma lithium levels in a double-blind, controlled trial. Proceedings of the Annual Meeting of the New Clinical Drug Evaluations Unit (NCDEU). Boca Raton, FL: US National Institute of Mental Health (NIMH); 1992
34. Jensen HV, Plenge P, Mellerup ET, et al. Lithium prophylaxis of manic-depressive disorder: daily lithium dosing schedule versus every second day. Acta Psychiatr Scand 1995; 92: 69-74
35. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-8
36. Suppes T, Baldessarini RJ, Faedda GL, et al. Discontinuing maintenance treatment in bipolar manic-depression: risks and implications. Harvard Rev Psychiatry 1993; I: 131-44
37. Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Therapeutics 1996; 3: 492-6
38. Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet 1970; II: 326-30
39. Melia PI. Prophylactic lithium: a double-blind trial in recurrent affective disorders. Br J Psychiatry 1970; 116: 621-4
40. Coppen A, Noguera R, Bailey J, et al. Prophylactic lithium in affective disorders. Lancet 1971; II: 275-9
41. Small JG, Small IF, Moore DF. Experimental withdrawal of lithium in recovered manic-depressive patients: a report of five cases. Am J Psychiatry 1971; 127: 1555-8
42. Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972; 2: 308-11
43. Hullin RP, McDonald D, Allsopp MNE. Prophylactic lithium in recurrent affective disorders. Lancet 1972: I: 1044-6
44. Fyrö B, Petterson U. A double blind study of the prophylactic effect of lithium in manic-depressive disease. Acta Psychiatr Scand 1977; 262: 17-22
45. Klein HE, Broucek B, Greil W. Lithium withdrawal triggers psychotic states. Br J Psychiatry 1981; 139: 255-64
46. Margo A, McMahon P. Lithium withdrawal triggers psychosis. Br J Psychiatry 1982; 141: 407-10
47. Mendlewicz J. Lithium discontinuation in bipolar illness: a double-blind prospective controlled study. In Corsini GB, editor. Current trends in lithium and rubidium therapy. Cambridge, MA: MTP Press, 1984: 135-41
48. Mander AJ, Loudon JB. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 1988; II: 15-7
49. Kocsis JH, Shaw ED, Stokes PE, et al. Neuropsychologic effects of lithium discontinuation. J Clin Psychopharmacol 1993; 13: 268-76
50. Grof P, Cakuls P, Dostal T. Lithium drop-outs, a follow-up study of patients who discontinued prophylactic lithium in recurrent affective disorders. Int Pharmacopsychiatry 1970; 5: 162-9
51. Schou M, Thomsen K, Baastrup PC. Studies on the course of recurrent endogenous affective disorders. Int Pharmacopsychiatry 1970; 5: 100-6
52. Lapierre YD, Gagnon A, Kokkinidis L. Rapid recurrence of mania following lithium withdrawal. Biol Psychiatry 1980; 15: 859-64
53. Christodoulou GN, Lykouras EP. Abrupt lithium discontinuation in manic-depressive patients. Acta Psychiatr Scand 1982; 65: 310-4
54. King JR, Hullin RP. Withdrawal symptoms from lithium. Br J Psychiatry 1983; 143: 30-5
55. Sashidaran SP, McGuire RJ. Recurrence of affective illness after withdrawal of long-term lithium treatment. Acta Psychiatr Scand 1983; 68: 126-33
56. Goodnik PJ. Clinical and laboratory effects of discontinuation of lithium prophylaxis. Acta Psychiat Scand 1985; 71: 608-14
57. Bouman TK, Niemantsverdriet-van Kampen JO, Sloof CJ. The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizoaffective disorders. J Affect Disord 1986; 11: 275-80
58. Mander AJ. Is there a lithium withdrawal syndrome? Br J Psychiatry 1986; 149: 498-501
59. Molnar G, Pristach C, Feeney GM, et al. A pilot study of managed lithium discontinuation. Psychopharmacol Bull 1988; 24: 217-9
60. Nilsson A, Axelsson R. Lithium discontinues. I. Clinical characteristics and outcome. Acta Psychiatr Scand 1990; 82: 433-8
61. Strober M, Morrell W, Lampert C, et al. Relapse follow ing discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: a naturalistic study. Am J Psychiatry 1990; 147: 457-61
62. Tondo L, Rudas N. Discontinuation of long-term treatment with lithium salts. Minerva Psichiatr (Rome) 1991; 32: 245-9
63. Koukopoulos A, Reginaldi D, Minnai G, et al. The long-term prophylaxis of affective disorders. In: Gessa G, Fratta W, Pani L, Serra G, editors. Advances in biochemical psychopharmacology. New York: Raven Press, 1996: 127-47
64. Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry 1995; 152: 1810-1
65. Baldessarini RJ, Tondo L, Faedda GL, et al. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996; 57: 441-8
66. Kraepelin E. Frequency of the individual forms-general course. In: Robertson GM, editor. Manic-depressive insanity and paranoia (1913). Translated by Barclay RM. Edinburgh: E&S Livingstone, 1921: 133-58
67. Dunner DL, Murphy D, Stallone F, et al. Episode frequency prior to lithium treatment in bipolar manic-depressive patients. Compr Psychiatry 1979; 20: 511-5
68. Zis AP, Grof P, Webster M, et al. Prediction of relapse in recurrent affective disorder. Psychopharmacol Bull 1980; 16: 47-50
69. Angst J. The course of affective disorders. Psychopathology 1986; 19 Suppl. 2: 47-52
70. Cutler NR, Post RM. Life course of illness in untreated manic-depressive patients. Compr Psychiatry 1982; 23: 101-15
71. Roy-Byrne P, Post RM, Uhde TW, et al. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand 1985; 71 Suppl. 317: 1-34
72. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993; 50: 448-55
73. Baldessarini RJ, Tondo L, Floris G, et al. Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study. Am J Psychiatry 1997; 154: 551-3
74. Viguera AC, Nonacs R, Baldessarini RJ, et al. Risks of discontinuing lithium maintenance in pregnant women with bipolar disorder [abstract]. Proc APA Ann Meeting, San Diego, CA, May, 1997
75. Post RM, Leverich GS, Altshuler LL, et al. Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992; 149: 1727-9
76. Tondo L, Baldessarini RJ, Fions G, et al. Effectiveness of retreating with lithium after its discontinuation in biopolar I and II disorders. Am J Psychiatry 1997; 154: 548-50
77. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: Molecular targets for lithium's actions. Arch Gen Psychiatry 1995; 52: 531-43
78. Viguera AC, Baldessarini RJ, Friedberg J. Risks of interrupting continuation or maintenance treatment with antidepressants in major depressive disorders. Harvard Rev Psychiatry. In press
79. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52: 189-92
80. Viguera AC, Baldessarini RJ, Hegarty JM, et al. Risk of discontinuing maintenance medication in schizophrenia. Arch Gen Psychiatry 1997; 4: 49-55